Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5824478 | Clinical Therapeutics | 2016 | 15 Pages |
Abstract
Results from this multicenter study provide, for the first time, a geographically diverse evaluation of daptomycin versus vancomycin for patients with vancomycin-susceptible MRSA bacteremia with vancomycin MIC values >1 µg/mL. Although the overall composite failure rates did not differ between the vancomycin and daptomycin groups when intensively matched according to risks for failure, the rates of acute kidney injury were significantly lower in the daptomycin group. These findings suggest that daptomycin is a useful therapy for clinicians treating patients who have MRSA bacteremia. Prospective, randomized trials should be conducted to better assess the potential significance of elevated vancomycin MIC.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Pamela A. PharmD, Darren L. PharmD, Annie PharmD, Joyce PharmD, Kenneth C. PharmD, Winter J. PharmD, Karri PharmD, Debra A. PharmD, Robert PharmD, Kimberly PharmD, Michael D. MD, James A. MD, Saira B. PharmD, Romic PharmD, Thomas PharmD, Katherine MD,